Shares of Strides Pharma Science Ltd jumped 10% on Thursday after the US Food and Drug Administration (USFDA) closed the inspection of the company's flagship Bengaluru facility with a Voluntary Action Indicated (VAI) classification.

Strides said the USFDA had conducted a current Good Manufacturing Practices (cGMP) inspection of its Bengaluru facility from May 12 to May 20, 2026. The inspection concluded with the issuance of a Form 483 containing five observations.

The company has since received the regulator's Establishment Inspection Report (EIR), confirming that the inspection was closed with a VAI classification, as reported by CNBC-TV18. An EIR is the USFDA's official report documenting a completed inspection, issued once the agency has closed its review of the facility.

What a Form 483 means

A Form 483 is issued by the USFDA at the close of an inspection when investigators have observed conditions that, in their judgment, may constitute violations of the US Food, Drug, and Cosmetic Act. The document lists the investigators' observations and does not in itself represent a final determination of regulatory compliance; companies typically respond with corrective and preventive actions.

How the USFDA classifies inspections

After reviewing an inspection, the USFDA classifies the outcome as No Action Indicated (NAI), Voluntary Action Indicated (VAI), or Official Action Indicated (OAI). A VAI classification indicates that objectionable conditions or practices were identified, but the agency is not prepared to take or recommend regulatory or administrative action, leaving remediation to the firm on a voluntary basis.

These classifications are closely tracked across India's pharmaceutical sector, where the United States is a major market for generic drugmakers. An OAI classification can escalate to enforcement measures such as warning letters or import alerts that restrict a facility's ability to supply the US market, while NAI and VAI outcomes do not trigger such agency action.

About the company

Strides Pharma Science Ltd is a pharmaceutical company headquartered in Bengaluru, India, with a business spanning regulated markets, including the United States. Its shares are listed and traded on Indian stock exchanges. Because US drug approvals and supply are tied to specific manufacturing sites, the regulatory standing of individual facilities is a routine consideration for companies supplying the US market.

The USFDA outcome follows the company's recently announced Q1 results, covered by CNBC-TV18.

Source: CNBC-TV18 Markets